SAN DIEGO, Sept. 15 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN - News) will be presenting at three upcoming conferences. A corporate overview will be provided by Berthold Lensker, PhD, Executive Director, European Operations of Amylin Pharmaceuticals and a clinical overview will be provided by David Kendall, MD, Executive Director, Medical Affairs of Amylin Pharmaceuticals at the Nordea Novel Anti-diabetics Seminar on Tuesday, September 19, 2006 at 4:30 a.m. PT / 1:30 p.m. CET in Copenhagen. A corporate overview will be provided by Dennis Kim, MD, Senior Director, Medical Affairs of Amylin Pharmaceuticals at the Oppenheimer Diabetes Conference on Thursday, September 21, 2006 at 5:25 a.m. PT / 8:25 a.m. ET in New York. A corporate overview will be provided by Dr. Lensker at the Merrill Lynch Global Pharmaceutical Biotechnology and Medical Devices Conference on Friday, September 22, 2006 at 5:30 a.m. PT / 1:30 p.m. UKT in London, UK.
